Elevation Oncology Analyst Ratings
Elevation Oncology Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/06/2023 | 941.45% | Wedbush | → $5 | Reiterates | Outperform → Outperform |
| 09/29/2023 | 212.43% | HC Wainwright & Co. | → $1.5 | Initiates Coverage On | → Buy |
| 06/05/2023 | 1149.74% | Wedbush | $4 → $6 | Maintains | Outperform |
| 05/30/2023 | 1566.32% | SVB Securities | $5 → $8 | Upgrades | Market Perform → Outperform |
| 03/10/2023 | 733.16% | Wedbush | → $4 | Reiterates | → Outperform |
| 01/09/2023 | 108.29% | SVB Leerink | $2 → $1 | Maintains | Market Perform |
| 11/10/2022 | — | JP Morgan | Downgrades | Neutral → Underweight | |
| 11/07/2022 | 316.58% | SVB Leerink | $11 → $2 | Downgrades | Outperform → Market Perform |
| 09/19/2022 | 1462.17% | HC Wainwright & Co. | → $7.5 | Assumes | → Buy |
| 08/08/2022 | — | JP Morgan | Downgrades | Overweight → Neutral | |
| 03/04/2022 | 4274.09% | Wedbush | $27 → $21 | Maintains | Outperform |
| 12/23/2021 | 2399.48% | HC Wainwright & Co. | → $12 | Initiates Coverage On | → Buy |
| 07/20/2021 | 5523.83% | Wedbush | → $27 | Initiates Coverage On | → Outperform |
| 07/20/2021 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 07/20/2021 | 4065.8% | SVB Leerink | → $20 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 11/06/2023 | 941.45% | Wedbush | → 5 美元 | 重申 | 跑贏大盤 → 跑贏大盤 |
| 09/29/2023 | 212.43% | HC Wainwright & Co. | → 1.5 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 06/05/2023 | 1149.74% | Wedbush | 4 美元 → 6 美元 | 維護 | 跑贏大盤 |
| 05/30/2023 | 1566.32% | SVB 證券 | 5 美元 → 8 美元 | 升級 | 市場表現 → 跑贏大盤 |
| 03/10/2023 | 733.16% | Wedbush | → 4 美元 | 重申 | → 跑贏大盤 |
| 01/09/2023 | 108.29% | SVB Leerink | $2 → $1 | 維護 | 市場表現 |
| 2022 年 10 月 11 日 | — | 摩根大通 | 降級 | 中性 → 體重不足 | |
| 2022 年 7 月 11 日 | 316.58% | SVB Leerink | 11 美元 → 2 美元 | 降級 | 跑贏大盤 → 市場表現 |
| 09/19/2022 | 1462.17% | HC Wainwright & Co. | → 7.5 美元 | 假設 | → 購買 |
| 08/08/2022 | — | 摩根大通 | 降級 | 超重 → 中性 | |
| 03/04/2022 | 4274.09% | Wedbush | 27 美元 → 21 美元 | 維護 | 跑贏大盤 |
| 12/23/2021 | 2399.48% | HC Wainwright & Co. | → 12 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 2021 年 7 月 20 日 | 5523.83% | Wedbush | → 27 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
| 2021 年 7 月 20 日 | — | Cowen & Co. | 啓動覆蓋範圍開啓 | → 跑贏大盤 | |
| 2021 年 7 月 20 日 | 4065.8% | SVB Leerink | → 20 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
What is the target price for Elevation Oncology (ELEV)?
Elevation Oncology（ELEV）的目標價格是多少？
The latest price target for Elevation Oncology (NASDAQ: ELEV) was reported by Wedbush on November 6, 2023. The analyst firm set a price target for $5.00 expecting ELEV to rise to within 12 months (a possible 941.45% upside). 8 analyst firms have reported ratings in the last year.
Wedbush於2023年11月6日公佈了Elevation Oncology（納斯達克股票代碼：ELEV）的最新目標股價。該分析公司將目標股價定爲5.00美元，預計ELEV將在12個月內升至12個月內（可能上漲941.45％）。去年有8家分析公司公佈了評級。
What is the most recent analyst rating for Elevation Oncology (ELEV)?
Elevation Oncology (ELEV) 的最新分析師評級是多少？
The latest analyst rating for Elevation Oncology (NASDAQ: ELEV) was provided by Wedbush, and Elevation Oncology reiterated their outperform rating.
Wedbush提供了Elevation Oncology（納斯達克股票代碼：ELEV）的最新分析師評級，Elevation Oncology重申了其跑贏大盤的評級
When is the next analyst rating going to be posted or updated for Elevation Oncology (ELEV)?
Elevation Oncology (ELEV) 的下一次分析師評級何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Elevation Oncology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Elevation Oncology was filed on November 6, 2023 so you should expect the next rating to be made available sometime around November 6, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Elevation Oncology的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。Elevation Oncology的最新評級是在2023年11月6日發佈的，因此您應該預計下一個評級將在2024年11月6日左右公佈。
Is the Analyst Rating Elevation Oncology (ELEV) correct?
分析師評級提升腫瘤學 (ELEV) 是否正確？
While ratings are subjective and will change, the latest Elevation Oncology (ELEV) rating was a reiterated with a price target of $0.00 to $5.00. The current price Elevation Oncology (ELEV) is trading at is $0.48, which is within the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但最新的Elevate Oncology（ELEV）評級得到了重申，目標股價爲0.00美元至5.00美元。目前Elevation Oncology（ELEV）的交易價格爲0.48美元，在分析師的預測範圍內。
譯文內容由第三人軟體翻譯。